GlassScriptPhysician profile
Jennifer E Taylor
NPI 1700148962
$2,656.82
in general payments reported to CMS, 2019-2025
21 companies · $300 in 2025
The $300 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2021: $86.24 · 2022: $586 · 2023: $913 · 2024: $505 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,718.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $391.22 | 2022-2025 | Verquvo, Steglatro, Capvaxive |
| Pfizer INC. | $352.31 | 2021-2025 | |
| Abbott Laboratories | $352.27 | 2019-2025 | Cardiomems, Mitraclip |
| Novartis Pharmaceuticals Corporation | $344.76 | 2021-2025 | |
| Heartflow, INC. | $153.90 | 2022-2023 | Ffrct |
| Impulse Dynamics (USA) INC. | $147.27 | 2023 | Optimizer |
| E.R. Squibb & Sons, L.L.C. | $143.46 | 2022-2024 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $128.36 | 2021-2023 | Xarelto |
| Abbvie INC. | $124.99 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $90.89 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $88.96 | 2022-2024 | Farxiga |
| Baxter Healthcare | $75.16 | 2023 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.19 | 2023-2024 | Jardiance |
| Kiniksa Pharmaceuticals, LTD. | $38.44 | 2023 | Arcalyst |
| Cvrx, INC. | $36.88 | 2022-2023 | Barostim Neo System |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $31.16 | 2019 | |
| Haemonetics Corporation | $25.77 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.10 | 2024 | Lifevest |
| Lilly USA, LLC | $23.10 | 2025 | Mounjaro, Zepbound |
| Alnylam Pharmaceuticals INC. | $22.97 | 2022 | |
| Irhythm Technologies, INC. | $15.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.